跳至主要内容
临床试验/NCT00967811
NCT00967811已完成2 期

An Open-Label, Phase 2 Study of Different Formulations (E1 and E2) of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)

Mati Therapeutics Inc.0 个研究点目标入组 83 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
83
主要终点
IOP change from baseline

研究概览

简要总结

The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects over 18 years of age diagnosed with ocular hypertension or open-angle glaucoma
  • Subjects who have a best corrected visual acuity of 20/100 or better

排除标准

  • Subjects who wear contact lenses
  • Subjects who have uncontrolled medical conditions
  • Subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic ocular topical medications
  • Subjects who have a history of chronic or recurrent inflammatory eye disease

研究组 & 干预措施

1. Formulation E1

Experimental

Formulation E1 of Latanoprost-PPDS

干预措施: Formulation E1 of L-PPDS (Drug)

2. Formulation E2

Experimental

Formulation E2 of Latanoprost-PPDS

干预措施: Formulation E2 of L-PPDS (Drug)

结局指标

主要结局

IOP change from baseline

时间窗: 12 weeks

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验